17 June 2019 - The U.S. Food and Drug Administration today approved Victoza (liraglutide) injection for treatment of paediatric patients 10 years or older with type 2 diabetes.
Victoza is the first non-insulin drug approved to treat type 2 diabetes in paediatric patients since metformin was approved for paediatric use in 2000. Victoza has been approved to treat adult patients with type 2 diabetes since 2010.
The efficacy and safety of Victoza for reducing blood sugar in patients with type 2 diabetes was studied in several placebo-controlled trials in adults and one placebo-controlled trial with 134 paediatric patients 10 years and older for more than 26 weeks.